Sustained Inhibition of Neurotransmitter Release from Nontransient Receptor Potential Vanilloid Type 1-Expressing Primary Afferents by μ-Opioid Receptor Activation-Enkephalin in the Spinal Cord
Authors:
- Hong-Yi ZhouHZHong-Yi Zhou
- Shao-Rui ChenSCShao-Rui Chen
- Hong ChenHCHong Chen
- Hui-Lin PanHPHui-Lin Pan
Open Access
- 1 November 2008
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 327 (2) , 375-382
Abstract
Removing transient receptor potential vanilloid type 1 (TRPV1)-expressing primary afferent neurons reduces presynaptic μ-opioid receptors but potentiates opioid analgesia. However, the sites and underlying cellular mechanisms for this paradoxical effect remain uncertain. In this study, we determined the presynaptic and postsynaptic effects of the μ-opioid receptor agonist [d-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin (DAMGO) using whole-cell patch-clamp recordings of lamina II neurons in rat spinal cord slices. Treatment with the ultrapotent TRPV1 agonist resiniferotoxin (RTX) eliminated TRPV1-expressing dorsal root ganglion neurons and their central terminals in the spinal dorsal horn and significantly reduced the basal amplitude of glutamatergic excitatory postsynaptic currents (EPSCs) evoked from primary afferents. Although RTX treatment did not significantly alter the concentration-response effect of DAMGO on evoked monosynaptic and polysynaptic EPSCs, it causes a profound long-lasting inhibitory effect of DAMGO on evoked EPSCs. Subsequent naloxone treatment did not reverse the prolonged inhibitory effect of DAMGO on evoked EPSCs. Furthermore, brief application of DAMGO produced a sustained inhibition of miniature EPSCs in RTX-treated rats. However, the concentration response and the duration of the effects of DAMGO on G protein-coupled inwardly rectifying K+ currents in lamina II neurons were not significantly different between vehicle- and RTX-treated groups. These data suggest that stimulation of μ-opioid receptors on non-TRPV1 afferent terminals causes extended inhibition of neurotransmitter release to spinal dorsal horn neurons. The differential effect of μ-opioid receptor agonists on different phenotypes of primary afferents provides a cellular basis to explain why the analgesic action of opioids on mechanonociception is prolonged when TRPV1-expressing primary afferents are removed.Keywords
This publication has 31 references indexed in Scilit:
- Resistance to morphine analgesic tolerance in rats with deleted transient receptor potential vanilloid type 1-expressing sensory neuronsNeuroscience, 2007
- Loss of TRPV1-Expressing Sensory Neurons Reduces Spinal μ Opioid Receptors But Paradoxically Potentiates Opioid AnalgesiaJournal of Neurophysiology, 2006
- Blocking μ opioid receptors in the spinal cord prevents the analgesic action by subsequent systemic opioidsBrain Research, 2006
- G protein βγ directly regulates SNARE protein fusion machinery for secretory granule exocytosisNature Neuroscience, 2005
- β-Arrestin2, interacting with phosphodiesterase 4, regulates synaptic release probability and presynaptic inhibition by opioidsProceedings of the National Academy of Sciences, 2005
- Distinct Domains of the μ-Opioid Receptor Control Uncoupling and InternalizationMolecular Pharmacology, 2004
- μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependenceNature, 2000
- Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin ReceptorScience, 2000
- Enhanced Morphine Analgesia in Mice Lacking β-Arrestin 2Science, 1999
- Mechanism of mu‐opioid receptor‐mediated presynaptic inhibition in the rat hippocampus in vitro.The Journal of Physiology, 1993